Redeye maintains its positive view on Orexo after the Q2 report. While the impact on lost exclusivity for Zubsolv results in lower, but stable, pharma quarterly revenues, a viable commercialisation model for the digital therapies is taking shape and the company continues investing in innovation and targeted market outreach. We maintain our valuation at SEK 80 per share.
